Among the 75 evaluable patients, the CBR was 35% (n = 26) at 16 weeks (95% CI, 0.24-0.46) and 29% (n = 22) at 24 weeks (95% CI, 0.20-0.41).
Six patients showed a complete or partial response (response rate of 8%).
Furthermore, they can be expressed in the breast epithelium.
The hope is that AR blockers, most commonly used in the treatment of prostate cancer, could be used on breast cancers that express ARs.“Since there are FDA-approved drugs that block the androgen receptor in men, the hope is that, if one could come up with a strategy that would demonstrate the effectiveness of these drugs in some women, that they could become clinically available for use in the clinic pretty quickly. Current efforts to employ ARs in breast cancer are focused on 3 prostate cancer drugs.
Whereas the androgen receptor (AR) is a common target in the treatment of prostate cancer, Michael F.
The effects of AR inhibition with enzalutamide were examined in vitro and in preclinical models of ER-positive and ER-negative breast cancers with AR expression.
The drug is currently being explored in the phase III ENDEAR trial, which will evaluate enzalutamide in combination with paclitaxel or as a monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC.
In another study looking at enzalutamide, which was published in Breast Cancer Research, the AR antagonist was used to elucidate the role of AR in preclinical models of ER-positive and ER-negative breast cancer.
Additionally, the median overall survival was 12 months.
Overall, 61% of patients (n = 72) experienced treatmentrelated adverse events (AEs), the most common of which were fatigue (30%), nausea (22%), and decreased appetite (11%).